U6508
UCN-01
≥97% (HPLC), PKC inhibitor, powder
동의어(들):
KW-2401
조직 및 계약 가격을 보려면 로그인를 클릭합니다.
크기 선택
보기 변경
제품정보 (DICE 배송 시 비용 별도)
실험식(Hill 표기법):
C28H26N4O4
CAS 번호:
Molecular Weight:
482.53
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
제품 이름
UCN-01, ≥97% (HPLC), powder
Quality Level
assay
≥97% (HPLC)
form
powder
optical activity
[α]20/D 130 to 160°, c = 0.2 in DMSO
storage condition
protect from light
color
light yellow
solubility
DMSO: >5 mg/mL, H2O: insoluble
storage temp.
2-8°C
SMILES string
[H][C@@]1(C[C@@H](NC)[C@H]2OC)N3C4=C(N([C@@]2(C)O1)C5=C6C=CC=C5)C6=C7C(C(N[C@@H]7O)=O)=C4C8=C3C=CC=C8
InChI
1S/C28H26N4O4/c1-28-25(35-3)15(29-2)12-18(36-28)31-16-10-6-4-8-13(16)19-21-22(27(34)30-26(21)33)20-14-9-5-7-11-17(14)32(28)24(20)23(19)31/h4-11,15,18,25,27,29,34H,12H2,1-3H3,(H,30,33)/t15-,18-,25-,27-,28+/m1/s1
InChI key
PBCZSGKMGDDXIJ-HQCWYSJUSA-N
Gene Information
Application
UCN-01 has been used to study checkpoint kinase-1 (CHK1) protein function in trophoblast stem (TS) cells. It has also been used to study UV-induced CHK1 phosphorylation in IB10 cells.
Biochem/physiol Actions
UCN-01 is a selective inhibitor for conventional PKC isotypes over novel PKC isotypes.
Features and Benefits
This compound is featured on the PKB/Akt and PKC pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
Preparation Note
UCN-01 is soluble in DMSO at a concentration that is greater than 5 mg/ml. However, it is insoluble in water.
저장 등급
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
S Akinaga et al.
Anti-cancer drug design, 15(1), 43-52 (2000-07-11)
UCN-01 (7-hydroxystaurosporine) is a protein kinase inhibitor which is under development as an anti-cancer agent in the USA and Japan. Although UCN-01 was originally isolated from the culture broth of Streptomyces sp. as a protein kinase C-selective inhibitor, its ultimate
Adrian M Senderowicz
The oncologist, 7 Suppl 3, 12-19 (2002-08-08)
Many tumor types are associated with genetic changes in the retinoblastoma pathway, leading to hyperactivation of cyclin-dependent kinases and incorrect progression through the cell cycle. Small-molecule cyclin-dependent kinase inhibitors are being developed as therapeutic agents. Of these, flavopiridol and UCN-01
Wuli Zhao et al.
Journal of experimental & clinical cancer research : CR, 37(1), 98-98 (2018-05-08)
A35 is a novel synthetic cyclizing-berberine recently patented as an antitumor compound. Based on its dual targeting topoisomerase (top) activity, A35 might overcome the resistance of single-target top inhibitors and has no cardiac toxicity for not targeting top2β. In this